Outcomes of implementation of the FilmArray meningoencephalitis panel in a tertiary hospital between 2017 and 2020.
Autor: | Teoh T; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland.; Centre for Interventions in Infection, Inflammation & Immunity (4i), Limerick, Ireland.; School of Medicine, University of Limerick, Limerick, Ireland., Powell J; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., O'Keeffe J; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., Donlon E; Department of Neurology, University Limerick Hospital Group, Limerick, Ireland., Dillon L; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., Lenihan M; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., Mostyn A; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., Power L; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland., Boers P; Department of Neurology, University Limerick Hospital Group, Limerick, Ireland., Stapleton PJ; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland.; School of Medicine, University of Limerick, Limerick, Ireland., O'Connell NH; Department of Clinical Microbiology, University Limerick Hospital Group, Limerick, Ireland.; Centre for Interventions in Infection, Inflammation & Immunity (4i), Limerick, Ireland.; School of Medicine, University of Limerick, Limerick, Ireland., Dunne CP; Centre for Interventions in Infection, Inflammation & Immunity (4i), Limerick, Ireland.; School of Medicine, University of Limerick, Limerick, Ireland. |
---|---|
Jazyk: | angličtina |
Zdroj: | PloS one [PLoS One] 2022 Mar 17; Vol. 17 (3), pp. e0265187. Date of Electronic Publication: 2022 Mar 17 (Print Publication: 2022). |
DOI: | 10.1371/journal.pone.0265187 |
Abstrakt: | Background: Acute meningoencephalitis is encountered commonly in the acute hospital setting and is associated with significant morbidity and mortality, in addition to significant healthcare costs. Multiplex PCR panels now allow syndromic testing for central nervous system infection. The BioFire® FilmArray® Meningoencephalitis (ME) allows testing of 14 target pathogens using only 0.2mls of cerebrospinal fluid (CSF). We conducted a retrospective observational study to assess the performance of the assay and secondarily to observe the clinical utility of negative results by comparing clinical outcomes of aseptic meningitis to bacterial and viral meningoencephalitis. Methods: Data for CSF samples tested using the FilmArray ME panel from October 2017 to October 2020 were analysed. Detection of bacterial and viral targets was analysed. Admission to critical care area, 90-day readmission rates, average length of stay and 30-day and 90-day mortality were analysed for three groups with following diagnoses: bacterial meningitis, viral meningoencephalitis, or aseptic meningitis. Results: From October 2017 to October 2020, 1926 CSF samples were received in the Clinical Microbiology laboratory. Of those, 543 CSF samples from 512 individual patients were tested using the FilmArray ME panel. Twenty-one bacterial targets and 56 viral targets were detected during the study period. For viral targets, the cumulative specificity was 98.9% (95% confidence interval: 93.1-99.9) when compared to the reference laboratory methods. The outcomes for 30- and 90-day mortality of the aseptic meningitis group were non-inferior relative to the viral meningoencephalitis and bacterial meningitis group. Patients with bacterial meningitis had a longer average length of stay. Aseptic meningitis was associated with a higher 90-day readmission rate than the other 2 groups, but without statistical significance. Conclusion: In our hands, implementation of the FilmArray ME panel was relatively straightforward. We experienced a transition in our workflow processes that enabled streamlining of CSF diagnostics and the safe removal of Gram staining in those samples being tested by this molecular assay. Coupled to this improvement, there was a positive clinical impact on patient care due to rapid turnaround time to results. Competing Interests: The authors have declared that no competing interests exist. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |